Harvard Bioscience (NASDAQ:HBIO – Get Free Report) and Alpha Teknova (NASDAQ:TKNO – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Harvard Bioscience and Alpha Teknova, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Harvard Bioscience | 1 | 1 | 1 | 0 | 2.00 |
| Alpha Teknova | 1 | 1 | 4 | 0 | 2.50 |
Harvard Bioscience presently has a consensus price target of $6.75, suggesting a potential downside of 19.16%. Alpha Teknova has a consensus price target of $8.75, suggesting a potential upside of 23.07%. Given Alpha Teknova’s stronger consensus rating and higher probable upside, analysts plainly believe Alpha Teknova is more favorable than Harvard Bioscience.
Profitability
This table compares Harvard Bioscience and Alpha Teknova’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Harvard Bioscience | N/A | N/A | N/A |
| Alpha Teknova | N/A | N/A | N/A |
Earnings and Valuation
This table compares Harvard Bioscience and Alpha Teknova”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Harvard Bioscience | N/A | N/A | N/A | ($2.31) | -3.61 |
| Alpha Teknova | $43.70 million | 8.74 | -$16.65 million | ($0.31) | -22.94 |
Harvard Bioscience has higher earnings, but lower revenue than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
80.9% of Harvard Bioscience shares are held by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are held by institutional investors. 17.0% of Harvard Bioscience shares are held by insiders. Comparatively, 13.2% of Alpha Teknova shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Alpha Teknova beats Harvard Bioscience on 5 of the 7 factors compared between the two stocks.
About Harvard Bioscience
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
About Alpha Teknova
Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
